• Degarelix Acetate: Optimized GnRH Antagonist Workflows in Re

  2026-05-20

  Degarelix acetate enables rapid, reproducible hormone suppression in both cellular and animal models, making it a cornerstone in prostate cancer research and pituitary hormone regulation studies. This article unpacks evidence-backed protocols, aggregation-aware handling, and troubleshooting tactics to maximize the reliability and translational value of your GnRH antagonist experiments.

• SN-38 Disrupts FUBP1–FUSE Binding: Novel Mechanism in Cancer

  2026-05-20

  The reference study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), beyond its established role as a DNA topoisomerase I inhibitor, directly impedes the oncogenic FUBP1–FUSE interaction. This dual mechanism expands the molecular rationale for using SN-38 in advanced cancer models and highlights new opportunities for targeted research in colon and liver cancer.

• Biomimetic Chromatography for Modeling Lung Drug Permeabilit

  2026-05-19

  The referenced study systematically compares biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane chromatography (IAM-LC) coupled with mass spectrometry to model pulmonary drug permeability. Its findings offer new strategies for high-throughput permeability screening, with implications for antiretroviral drug development and translational research.

• Neuromedin S (rat): Technical Guidance for GPCR Signaling Wo

  2026-05-19

  Neuromedin S (rat) is a chemically defined peptide agonist for targeted activation of neuromedin U receptor signaling in rat-based GPCR/G protein pathway research. It is intended for controlled laboratory assays investigating mechanisms such as energy homeostasis regulation and stress response, but is not suitable for diagnostic or therapeutic applications. Proper handling and protocol adherence are critical to maintain experimental reproducibility.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling

  2026-05-18

  Leverage 2,5-di-tert-butylbenzene-1,4-diol (BHQ) for precise, reproducible control over calcium homeostasis in stem cell and vascular studies. This guide delivers actionable workflow enhancements and troubleshooting strategies, integrating the latest published breakthroughs with hands-on protocol optimization.

• Chlorpromazine in Hepatic and Dopaminergic Research: Cellula

  2026-05-18

  Explore the multidimensional role of chlorpromazine in neuroscience and hepatic cellular research. This article unpacks its antipsychotic and antiemetic mechanisms with a focus on cellular microenvironments, highlighting recent advances in nanoparticle-liver interactions and their implications for antipsychotic research.

• Cell lysis buffer for WB and IP: Optimized Protein Extractio

  2026-05-17

  Unlock reproducible, non-denaturing protein extraction for advanced tumor microenvironment research with APExBIO’s Cell lysis buffer for WB and IP. This protocol-driven guide details workflow enhancements, troubleshooting strategies, and translational best practices validated by recent breakthroughs in prostate cancer chemoresistance assays.

• Alfuzosin HCl in Gastroretentive BPH Research: Protocols & I

  2026-05-16

  Alfuzosin HCl, a selective α1 adrenoceptor antagonist, enables precise modeling of lower urinary tract smooth muscle relaxation and sustained-release delivery in benign prostatic hyperplasia research. This guide explores protocol parameters, experimental workflows, and troubleshooting strategies leveraging APExBIO’s high-purity Alfuzosin Hydrochloride, grounded in recent advances in gastroretentive drug delivery.

• VX-702: Redefining p38α MAPK Inhibition for Translational Re

  2026-05-15

  Explore the advanced selectivity of VX-702, a potent p38α MAPK inhibitor, and discover how new mechanistic insights reshape its value for inflammation and disease modeling. This article uniquely synthesizes structural and assay implications to guide next-generation research.

• Structural Dissection and Affinity Tuning of CD38 CAR Binder

  2026-05-15

  This study provides detailed structural insights into how two distinct CD38-targeting CAR binders recognize and inhibit their antigen, enabling rational tuning of CAR affinity to balance tumor targeting and safety. The findings offer a practical blueprint for optimizing CAR-T cell therapies targeting hematological malignancies and highlight considerations for reducing off-tumor cytotoxicity.

• IEM 1460: Advanced AMPA Receptor Blocker for Neuroprotection

  2026-05-14

  IEM 1460 stands out as a highly selective AMPA receptor blocker, enabling precise dissection of excitatory synaptic transmission and neuroprotection mechanisms. This article translates cutting-edge reference findings into actionable experimental strategies, highlighting protocol enhancements, troubleshooting tips, and workflow innovations for neuroscience research.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix T

  2026-05-14

  A recent multi-center study identifies 'testosterone bounce'—a fluctuation above and below 20 ng/dL during therapy—as a novel predictor of overall and cancer-specific survival in prostate cancer patients treated with the GnRH receptor antagonist Degarelix acetate. These findings refine prognostic assessment beyond conventional PSA-based monitoring and highlight dynamic testosterone profiling as a key tool in hormone therapy research.

• ARCA EGFP mRNA (5-moUTP): Elevating Polyadenylated mRNA Assa

  2026-05-13

  ARCA EGFP mRNA (5-moUTP) redefines fluorescence-based transfection controls, merging high translation efficiency with minimized innate immune activation. This guide details actionable workflows, optimal conditions, and troubleshooting insights to ensure robust, reproducible results in mammalian cell assays.

• FPH1 (BRD-6125) Transforms Hepatocyte Proliferation Assays

  2026-05-13

  FPH1 (BRD-6125) redefines functional hepatocyte expansion by enabling robust, donor-independent culture and enhancing assay reproducibility. Its ability to elevate albumin secretion and CYP3A4 activity empowers advanced workflows in drug discovery and regenerative medicine.

• Myriocin Reverses dAGE-Induced Metabolic Dysfunction via AMP

  2026-05-12

  This study reveals that Myriocin, a selective serine palmitoyltransferase inhibitor, restores metabolic homeostasis in mice exposed to high levels of dietary advanced glycation end products (dAGEs) by activating the AMPK-PGC1α axis and enhancing mitochondrial function. The findings advance understanding of sphingolipid metabolism's role in obesity and suggest new avenues for metabolic syndrome intervention.

16656 records 1/1111 page Next 12345 下5页 Last page